المراجع: الجزء الأول
1. Role of androgens in growth and development of the fetus, child, and adolescent. Rosenfield R.L. Adv Pediatr. 19 (1972) 172-213
2. Metabolism of Anabolic Androgenic Steroids, Victor A. Rogozkin, CRC Press 1991
3. Androgens and Erythropoeisis. J Clin Pharmacol. Feb-Mar 1974 p94101
4. Effects of various modes of androgen substitution therapy on erythropoiesis. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Eur J Med Res 1997 Jul 28;2(7):293-8
5. Testosterone increases lipolysis and the number of betaadrenoceptors in male rat adipocytes. Xu XF, De Pergola G, Bjorntorp P. Endocrinology 1991 Jan;128(1):379-82
6. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinol 126 (1990) 1229-34
7. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Seidell JC, Bjorntorp L, Sjostrom L, et al. Metabolism 39 (1990) 897-901
8. Effects of testosterone and estrogens on deltoid and trochanter adipocytes in two cases of transsexualism. Vague J, Meignen J.M. and Negrin J.F. Horm. Metabol. Res. 16 (1984) 380-381
9. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Fernando A, Tipton K, Doyle D et al. Am J. Physiol (Endocrinology and Metabolism) 38:E864-71,1998.
10. Glucorticoid antagonism by exercise and androgenic-anabolic steroids. Hickson RC, Czerwinski SM, Falduto MT, Young AP. Med Sci Sports Exerc 22 (1990) 331-40
11. Binding of glucorticoid antagonists to androgen and glucorticoid hormone receptors in rat skeletal muscle. Danhaive PA, Rousseau GG. J Steroid Biochem Mol Biol 24 (1986) 481-71
12. Evidence for a sex-dependent anabolic response to androgenic steroids mediated by muscle glucorticoid receptors in the rat. Danhaive PA, Rousseau GG. J. Steroid Biochem Mol Biol. 29 (1988) 575-81
13. Glucorticoid antagonism by exercise and androgenic-anabolic steroids. Hickson RC, Czerwinski SM, Falduto MT, Young AP. Med Sci Sports Exerc 22 (1990) 331-40
14. The source of excess creatine following methyl testosterone. Samuels L.T., Sellers D.M., McCaulay C.J.J. Clin. Endocrinol. Metab. 6 (1946) 655-63
15. Ontogeny of growth hormone, insulin-like growth factor, estradiol and cortisol in the growing lamb: effect of testosterone. Arnold AM, Peralta JM,Tonney MI.J Endocrinol 150 (1996) 391-9 12.Jun;130(6):367783.81, 2001.
16. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269 (1995) E820-6
17. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. Mausas N, Hayes V, Welch S et al. J Clin Endocrin Metab 83 (1998) 1886-92
18. Endocrinology 114(6):2100-06 1984 June,”Relative Binding Affinity of Anabolic-Androgenic Steroids…Saartok T; Dahlberg E; Gustafsson JA
19. Endocrinology 114(6):2100-06 1984 June, “Relative Binding Affinity of Anabolic-Androgenic Steroids…)Saartok T; Dahlberg E; Gustafsson JA
20. Sex Hormone-Binding Globulin Response to the Anabolic Steroid Stanozolol: Evidence for Its Suitability as a Biological Androgen Sensitivity Test. J Clin Endocrinol Metab 8:1195,1989
21. Twenty two weeks of transdermal estradiol increases sex hormonebinding globulin in surgical menopausal women. Eur J Obstet Gynecol Reprod Biol 73: 149-52,1997
22. Aromatization of androgens by muscle and adipose tissue in vivo. Longcope C, Pratt JH, Schneider SH, Fineberg SE. J Clin Endocrinol Metab 1978 Jan;46(1):146-52
23. The aromatization of androstenedione by human adipose and liver tissue. J Steroid Biochem. 1980 Dec;13(12):1427-31.
24. Aromatase expression in the human male. Brodie A, Inkster S, Yue W. Mol Cell Endocrinol 2001 Jun 10;178(1-2):23-8
25. A review of brain aromatase cytochrome P450. Lephart ED. Brain Res Brain Res Rev 1996 Jun;22(1):1-26
26. Aromatization by skeletal muscle. Matsumine H, Hirato K, Yanaihara T, Tamada T, Yoshida M. J Clin Endocrinol Metab 1986 Sep;63(3):717-20
27. Pentose Cycle Activity in Muscle from Fetal, Neonatal and Infant Rhesus Monkeys. Arch Biochem Biophys 117:275-81 1966
28. The pentose phosphate pathway in regenerating skeletal muscle. Biochem J 170:17-1978
29. Aromatization of androgens to estrogens mediates increased activity of glucose 6-phosphate dehydrogenase in rat levator ani muscle. Endocrinol 106(2):440-43 1980
30. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. J steroid Biochem Mol Bio 41:541-3,1992
31. Activation of the somatotropic axis by testosterone in adult males: Evidence for the role of aromatization. J Clin. Endocrinol Metab 76:140712 1993
32. Testosterone administration increases insulin-like growth factorlevels in normal men. J Clin Endocrinol Metab 77(3):776-9 1993
33. Androgen-stimulated pubertal growth:the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-l in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 76(4)996-1001 1993
34. Modulation of the cytosolic androgen receptor in striated muscle by sex steroids. Endocrinology. 1984 Sep;115(3):862-6.
35. Effect of estrogen-serotonin interactions on mood and cognition. Zenab Amin et al. Behav Cogn Neurosci Reviews 4(1) 2005:43-58
36. Serotonin and the sleep/wake cycle: special emphasis on miscodialysis studies. Chiara M Portas et al. Progress in Neurology 60(200) 13-35.
37. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport 2004 Dec 3;15(17):2571-4
38. Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Narita M et al. Biochem Biophys Res Commun 2003 Nov 14;311(2)264-6
19. Endocrinology 114(6):2100-06 1984 June, “Relative Binding Affinity of Anabolic-Androgenic Steroids…)Saartok T; Dahlberg E; Gustafsson JA
20. Sex Hormone-Binding Globulin Response to the Anabolic Steroid Stanozolol: Evidence for Its Suitability as a Biological Androgen Sensitivity Test. J Clin Endocrinol Metab 8:1195,1989
21. Twenty two weeks of transdermal estradiol increases sex hormonebinding globulin in surgical menopausal women. Eur J Obstet Gynecol Reprod Biol 73: 149-52,1997
22. Aromatization of androgens by muscle and adipose tissue in vivo. Longcope C, Pratt JH, Schneider SH, Fineberg SE. J Clin Endocrinol Metab 1978 Jan;46(1):146-52
23. The aromatization of androstenedione by human adipose and liver tissue. J Steroid Biochem. 1980 Dec;13(12):1427-31.
24. Aromatase expression in the human male. Brodie A, Inkster S, Yue W. Mol Cell Endocrinol 2001 Jun 10;178(1-2):23-8
25. A review of brain aromatase cytochrome P450. Lephart ED. Brain Res Brain Res Rev 1996 Jun;22(1):1-26
26. Aromatization by skeletal muscle. Matsumine H, Hirato K, Yanaihara T, Tamada T, Yoshida M. J Clin Endocrinol Metab 1986 Sep;63(3):717-20
27. Pentose Cycle Activity in Muscle from Fetal, Neonatal and Infant Rhesus Monkeys. Arch Biochem Biophys 117:275-81 1966
28. The pentose phosphate pathway in regenerating skeletal muscle. Biochem J 170:17-1978
29. Aromatization of androgens to estrogens mediates increased activity of glucose 6-phosphate dehydrogenase in rat levator ani muscle. Endocrinol 106(2):440-43 1980
30. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. J steroid Biochem Mol Bio 41:541-3,1992
31. Activation of the somatotropic axis by testosterone in adult males: Evidence for the role of aromatization. J Clin. Endocrinol Metab 76:140712 1993
32. Testosterone administration increases insulin-like growth factorlevels in normal men. J Clin Endocrinol Metab 77(3):776-9 1993
33. Androgen-stimulated pubertal growth:the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-l in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 76(4)996-1001 1993
34. Modulation of the cytosolic androgen receptor in striated muscle by sex steroids. Endocrinology. 1984 Sep;115(3):862-6.
35. Effect of estrogen-serotonin interactions on mood and cognition. Zenab Amin et al. Behav Cogn Neurosci Reviews 4(1) 2005:43-58
36. Serotonin and the sleep/wake cycle: special emphasis on miscodialysis studies. Chiara M Portas et al. Progress in Neurology 60(200) 13-35.
37. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport 2004 Dec 3;15(17):2571-4
38. Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Narita M et al. Biochem Biophys Res Commun 2003 Nov 14;311(2)264-6
39. Premenstrual Syndrome. Dickerson LM et al. Am Fam Physician 2003 Apr 15;67(8):1743-52
40. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol. 2003 Dec;91(3):596-602.
41. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs. 1998 Dec;56(6):1125-40. Review.
42. Exemestane: a review of its clinical efficacy and safety. Breast. 2001 Jun;10(3):198-208.
43. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol. 1992 Jan;10(1):111-6.
44. Neural androgen receptor regulation: effects of androgen and antiandrogen. Lu S, Simon NG, Wang Y, Hu S. J Neurobiol 1999 Dec;41(4):505-12
45. A comparative study of the metabolic fate of testosterone, 17alpha-methyltestosterone, 19-nor-testosterone, 17alpha-methyl-19nor-testosterone and 17alpha-methyl-estr-5(10)-ene-17beta-ol-3-one in normal males. Dimick D, Heron M, et al. Clin Chim Acta 6(1961) 63-71.
46. Unique steroid congeners for receptor studies. Ojasoo T, Raynaud J. Cancer Research 38 (1978) 4186-98
47. Cytosolic androgen receptor in regenerating rat levator ani muscle. Max S.R. Mufti S, Carlson B.M.J Biochem 200 (1981) 77
48. In vitro binding and metabolism of androgens in various organs: a comparative study. Kreig M., Voigt K.D. J Steroid Biochem 7 (1976) 1005
49. Androgen concentrations in sexual and non-sexual skin as well as striated muscle in man. Deslypere J.P., Sayed A., Verdonck L., Vermeulen A. J Steroid Biochem 13 (1980) 1455-8
50. Age related testosterone level changes and male andropause syndrome. Wu CY, Yu TJ, Chen MJ. Chang Gung Med J. 2000 Jun;23(6):348-53.
51. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Schubert M, Bullmann C et al. Horm Res. 2003;60(1):21-8.
52. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Zgliczynski S, Ossowski M et al. Atherosclerosis. 1996 Mar;121(1):35-43.
53. Testosterone and other anabolic steroids as cardiovascular drugs. Shaprio J, Christiana J et al. Am J Ther 1999 May;6(3):167-74
54. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Kapoor D, Jones TH. Drugs Aging. 2008;25(5):357-69.
55. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. Malkin CJ, Pugh PJ et al. J Clin Endocrinol Metab. 2004 Jul;89(7):3313-8.
56. Adverse events associated with testosterone administration. Basaria S, Coviello A, Travison T. et al. NEJM July 8, 2010, Vol. 363, N. 2.
57. Vascular reactivity in hypogonadal men is reduced by androgen substitution. Zitzmann M, Brune M, Nieschlag E. J Clin Endocrinol Metab. 2002 Nov;87(11):5030-7.
58. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Guay AT, Perez JB, Fitaihi WA, Vereb M.Endocr Pract. 2000 Mar-Apr;6(2):132-8.
59. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism the androgen receptor gene: a longitudinal pharmacogenetic stud, Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. J Clin Endocrin, Metab. 2003 May;88(5):2049-54.
60. Obstructive sleep apnea syndrome induced by testosteron administration. Sandblom RE, Matsumoto AM, Schoene RB, Lee KA, Giblin EC, Bremner WJ, Pierson DJ. N Engl J Med. 1983 Mar 3;308(9):508-10.
61. Testosterone therapy and obstructive sleep apnea: is there a real connection? Hanafy HM. J Sex Med. 2007 Sep;4(5):1241-6. Epub 2007 21.
62. Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function. Maki PM, Ernst M et al. J Clin Endocrinol Metab. 2007 Nov;92(11):4107-14. Epub 2007 Aug 28.
63. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. Vaughan C, Goldstein FC, Tenover JL. J Androl. 2007 NovDec;28(6):875-82. Epub 2007 Jul 3.
64. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Cherrier MM, Matsumoto AM et al. Neurology. 2005 Jun 28;64(12):2063-8.
65. Characterization of Verbal and Spatial Memory Changes from Moderate to Supraphysiological increases in Serum Testosterone in Healthy Older Men. M Cherrier et al. Psychoneuroendocrinology 2007 Jan 32(1): 72-79.
66. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. Agostoni A, Cicardi M. J Allergy Clin Immunol. 1980 Jan;65(1):75-9.
67. Endocrine and intracrine sources of androgens in women:inhibition of breast cancer and other roles of androgens and their precursor
68. Effects of androgens on haemostasis. Winkler UH. Maturitas. 1996 Jul;24(3):147-55.
69. Anabolic steroids and fibrinolysis. Lowe GD. Wien Med Wochenschr. 1993;143(14-15):383-5.
70. Plasma fibrinolytic activity following oral anabolic steroid therapy. Walker ID, Davidson JF. Thromb Diath Haemorrh. 1975 Sep 30;34(1):23645.
71. The effect of mesterolone on sperm count, on serum follicle stimulating hormone, luteinizing hormone, plasma testosterone and outcome in idiopathic oligospermic men. Varma TR, Patel RH. Int J Gynaecol Obstet. 1988 Feb;26(1):121-8.
72. Mesterolone treatment of patients with pathospermia. Szöllösi J, Falkay GY, Sas M. Int Urol Nephrol. 1978;10(3):251-6.
73. Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group. Wilson DM, McCauley E, Brown DR, Dudley R. Pediatrics. 1995 Dec;96(6):1095-100.
74. Growth and growth hormone responses to oxandrolone in with constitutional delay of growth and puberty (CDGP). Clayton Shalet SM, Price DA, Addison GM. Clin Endocrinol (Oxf). 1900 Aug;29(2):123-30.
75. Oxandrolone in constitutional delay of growth: analysis of growth patterns up to final stature. Bassi F, Neri AS, Gheri RG, Chen Serio M.J Endocrinol Invest. 1993 Feb;16(2):133-7.
76. Oxandrolone treatment of constitutional short stature in box during adolescence: effect on linear growth, bone age, pubic hall, testicular development. Marti-Henneberg C, Niirianen AK, Rappaport Pediatr. 1975 May;86(5):783-8.
77. Anabolic steroids in postmenopausal osteoporosis. Need AG et al. Wien Med Wochenschr. 1993;143(14-15):392-5.
78. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. Clin Rheumatol. 1995 Sep;14 Suppl 3:32-9.
79. Nandrolone decanoate:pharmacological properties and therapeutic use in osteoporosis. Geusens P. Clin Rheumatol. 1995 Sep;14 Suppl 3:32-9.
80. Nandrolone decanoate for men with osteoporosis. Hamdy RC, Moore SW, Whalen KE, Landy C. Am J Ther. 1998 Mar;5(2):89-95.
81. Effects of nandrolone decanoate on bone mass in established osteoporosis. Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG. Maturitas. 1993 Nov;17(3):211-9.
82. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. Clin Rheumatol. 1995 Sep;14 Suppl 3:32-9.
83. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Lippi G, Guidi G, Ruzzenente O, Braga V, Adami S. Scand J Clin Lab Invest. 1997 Oct;57(6):507-11.
84. Turner’s syndrome. Guarneri MP, Abusrewil SA et al. J Pediatr Endocrinol Metab. 2001 Jul;14 Suppl 2:959-65.
85. Underweight, overweight and obesity as risk factors for mortality and hospitalization. Gunilla Ringbäck Weitoft. Scandinavian Journal of Public Health, Vol. 36, No.2, 169-176 (2008)
86. Catabolic illness. Strategies for enhancing recovery. Wilmore DW.N Engl J Med. 1991 Sep 5;325(10):695-702.
87. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. Storer TW, Woodhouse DJ et al. J Clin Endocrinol Metab. 2005 Aug;90(8):4474-82. Epub 2005 May 24.
88. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. Hengge UR, Stocks K et al. AIDS. 2003 Mar 28;17(5):699-710.
89. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. Grunfeld C, Kotler DP et al. J Acquir Immune Defic Syndr. 2006 Mar;41(3):304-14.
90. Use of anabolic steroids and associated health risks among gay men attending London gyms. Bolding G, Sherr L, Elford J. Addiction. 2002 Feb;97(2):195-203.
91. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence. Grundy S et al. J Lipid Res 1999 40:229-34.
92. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Kouri EM et al. Clin J Sport Med 1996 Jul;6(3):152-7.
93. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261:1165-8,1989
94. High-Density Lipoprotein Cholesterol Is Not Decreased if an Aromatizable Androgen Is Administered. Metabolism, 39:69-74,1990
95. Relationship of cardiac size to maximal oxygen uptake and body size in men and women. Hutchinson PL, Cureton KJ, Outz H, Wilson G. Int J Sports Med. 1991 Aug;12(4):369-73.
96. Androgenic anabolic steroids also impair right ventricular function. Kasikcioglu E et al. Int J Cardiol 2008 Feb 11 E Pub.
97. Cardiac effects of anabolic steroids. Payne J. et al. Heart 2004; 90:473-75.
98. Adverse effects of anabolic androgenic steroids on the cardiovascular, metabolic and reproductive systems of anabolic substance abusers. Tuomo Karila. Publications of the National Public Health Institute ISBN 951-740-388-2
99. Absense of left ventricular wall thickening in athletes engaged in intense power training. Pelliccia A et al. Am J Cardiol 1993; 72: 1048-54.
100. Left ventricular hypertrophy by Sokolow-Lyon voltage criterion predicts mortality in overweight hypertensive subjects. Antikainen RL, Grodzicki T. J Hum Hypertens. 2008 Aug 28. [Epub]
101. Hypertensive heart disease. A complex syndrome or a hypertensive cardiomyopathy? Lip GYH et al. Eur Heart J 2000;21:1653-65.
102. Adverse effects of anabolic androgenic steroids on the cardiovascular, metabolic and reproductive systems of anabolic substance abusers. Tuomo Karila. Publications of the National Public Health Institute ISBN 951-740-388-2
103. Left ventricular hypertrophy and QT dispersion in hypertension. Mayet J et al. Hypertension 1996; 28:791-96.
104. Cardiac arrest following anaesthetic induction in a world-class bodybuilder. Angelilli A, Katz ES, Goldenberg RM. Acta Cardiol. 2005 Aug;60(4):443-4.
105. Effects of training on left ventricular structure and function. An echocardiographic study. Shapiro CM et al. Br. Heart J 1983; 50: 534-39.
106. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Urhausen A, Albers T, Kindermann W. Heart. 2004 May;90(5):496-501.
107. The effects of anabolic-androgenic steroids on primary myocardial cell cultures. Melchert RB et al. Med Sci Sports Exerc 1992; 24:266-12
108. Cardiovascular effects of anabolic-androgenic steroids. Melchert RB et al. Med Sci Sports Exerc 1995;27: 1252-62
109. Cause and manner of death among users of anabolic androgenic steroids. Thiblin I et al. J Forensic Sci 2000;45:16-23
110. Anabolic steroid abuse and cardiac death. Kennedy MC et al. Med J Aust 1993; 158:346-48.
111. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Nieminen MS et al. Eur Heart J 1996;17:1576-83.
112. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Fineschi V et al. Int J Legal Med 2007 Jan;121(1):48-53. Epub 2005 Nov 15. Review.
113. Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS). Grace F, Sculthorpe N, Baker J, Davies B. J Sci Med Sport. 2003 Sep;6(3):307-12.
114. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? A Urhausen et al. Heart 2004;90:496-501.
115. Cardiovascular side effects of anabolic-androgenic steroids. Herz. 2006 Sep;31(6):566-73.
116. Anabolic steroids and fibrinolysis. Lowe GD.Wien Med Wochenschr. 1993;143(14-15):383-5.
117. Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels. Walker ID, Davidson JF, Young P, Conkie JA. Thromb Diath Haemorrh. 1975 Sep 30;34(1):106-14.
118. Depo-Testosterone. Pharmacia. U.S. Prescribing Information. Revised August 2002.
119. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol. Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA. 1995 Aug;49(4):282-8.
120. Raised concentrations of C reactive protein in anabolic steroid using bodybuilders.FM Grace, B Davies et al. Br J Sports Med 2004;38:9798.
121. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Ajayi AA, Mathur R, Halushka PV. Circulation
122. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Ferenchick G, Schwartz D, Ball M, Schwartz K. Am J Med Sci. 1992 Feb;303(2):78-82.
123. Pulmonary embolism associated with the use of anabolic steroids. Liljeqvist S, Helldén A, Bergman U, Söderberg M. Eur J Intern Med. 2008 May;19(3):214-5. Epub 2007 Sep 19.
124. Coronary thrombosis and ectasia of coronary arteries after longterm use of anabolic steroids. Tischer KH, Heyny-von Haussen R, Mall G, Doenecke P.Z Kardiol. 2003 Apr;92(4):326-31.
125. Massive pulmonary embolus and anabolic steroid abuse. Gaede JT, Montine TJ.JAMA. 1992 May 6;267(17):2328-9.
126. Steroid anabolic drugs and arterial complications in an athlete–a case history. Laroche GP. Angiology. 1990 Nov;41(11):964-9.
127. Death caused by pulmonary embolism in a body builder taking anabolic steroids (metanabol). Siekierzyfska-Czarnecka A, Polowiec Z, Kulawifska M, Rowinska-Zakrzewska E. Wiad Lek. 1990 Oct 1-15;43(1920):972-5.
128. Coagulation abnormalities associated with the use of anabolic steroids. Ansell JE, Tiarks C, Fairchild VK. Am Heart J. 1993 Feb;125(2 Pt 1):367-71.
129. Hematocrit and the risk of cardiovascular disease–the Framingham study: a 34-year follow-up. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Am Heart J. 1994 Mar;127(3):674-82.
130. Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse. M R Graham, FM Grace et al. Br. J Sports Med. 2006;40:544-48.
131. Homocysteine and cardiovascular disease: time to routinely screen and treat? P. OʻCallaghan et al. Br J Cario 2003; 10(2) 115-7.
132. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci 1994;91:6369-73
133. Homocystinuria: metabolic studies on three patients. Brenton D et al. J Pediatr 1966;67-58-68.
134. Homocysteine, and atherogenic stimulus, reduces protein C activation by arterial and venious endothelial cell. Rogers G et al. Blood 1990;75:895-901.
135. Homocysteinethiolactone disposal by human arterial endothelial cells and serum in vitro. Dudman N et al. Atherioscler Thromb 1991;11:663-70.
136. Plasma homocysteine levels and mortality in patients with coronary artery disease. Nygard O et al. N Engl J Med 1997;337:230-6.
137. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. Giltay EJ, Hoogeveen EK et al. J Clin Endocrinol Metab. 1998 Feb;83(2):550-3.
138. Homocysteine levels in men and women of different ethnic and cultural background living in England. Cappuccio FP, Bell R. et al. Atherosclerosis. 2002 Sep;164(1):95-102.
139. Hyperhomocysteinemia in bodybuilders taking anabolic steroids. Ebenbichler CF, Kaser S et al. Eur J Intern Med. 2001 Feb;12(1):43-47
140. Homocysteine induced cardiovascular events: a consequenca long term anabolic-androgenic steroid (AAS) abuse. M R Graham Grace et al. Br. J Sports Med. 2006;40:544-48.
141. The effect of supraphysiologic doses of testosterone on fastina total homocysteine levels in normal men. Zmuda JM, Bausserman Maceroni D, Thompson PD. Atherosclerosis. 1997 Apr;130(1-2):199-202
142. Hypertension, stroke, and endothelium. F. Consentino, M. Volna Cur Hypertension Rep. January 2005:7(1); 68-71
143. Differences in Vascular Reactivity Between Men and Women.Bob Schank, MS et al. Angiology, Vol. 57, No. 6,702-708 (2007)
144. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids Ebenbichler CF, Sturm W et al. Atherosclerosis. 2001 Oct;158(2):483-90.
145. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Lane HA et al. Eur J Clin Invest 2006 Jul; 36(7): 483-8.
146. The more effective immune system of women against infectious agents. Müller HE.Wien Med Wochenschr. 1992;142(17):389-95
147. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Ansar AS et al. Human Repr Upd. 11(4) 411-23.2005.
148. Sex hormones and the immune response in humans. A Bouman et al. Human Reprod Update 11(4) pp.411-23,2005.
149. Effect of a single administration of testosterone on the immune response and lymphoid tissue in mice. Fuji H et al. Immunology 20:31526.1975.
150. Estrogens and health in males. Lombardi G, Zarrilli S et al. Mol Cell Endocrinol. 2001 Jun 10;178(1-2):51-5.
151. Dichotomy of glucocorticoid action in the immune system. Asadullah K, Schäcke H, Cato AC. Trends Immunol. 2002 Mar;23(3):120-2
152. Anabolic steroid effects on immune function: differences between analogues. Mendenhall CL, Grossman CJ, et al. J Steroid Biochem Mol Biol. 1990 Sep;37(1):71-6.
153. A trial of testosterone therapy for HIV-associated weight loss. Coodley GO, Coodley MK. AIDS. 1997 Sep;11(11):1347-52.
154. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting. J Gold, 1 MJ Batterham et al. HIV Medicine (2006), 7, 146-155
155. The effect of anabolic steroids and strength training on the immune response.L Calabrese et al. Med and Sci in Sports and Exer. 21(4) pp. 386-92, 1983.
156. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Ballal SH, Domoto DI, Polack DC, Marciulonis P, Martin KJ. Am J Kidney Dis. 1991 Jan;17(1):29-33.
157. Use of androgens in patients with renal failure. Johnson CA. Semin Dial. 2000 Jan-Feb;13(1):36-9.
158. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. Johansen KL, Mulligan , Schambelan M. JAMA. 1999 Apr 14;281(14):1275-81.
159. Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Johansen KL. Semin Dial. 2004 MayJun;17(3):202-8.
160. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Modlinski R, Fields KB. Curr Sports Med Rep. 2006 Apr;5(2):104-9.
161. Wilms tumor in an adult associated with androgen abuse. Prat J, Gray GF, Stolley PD, Coleman JW.JAMA. 1977 May 23;237(21):2322-3
162. Anabolic steroid abuse and renal cell carcinoma. Martorana G, Concetti S, Manferrari F, Creti S.J Urol. 1999 Dec;162(6):2089
163. Anabolic steroid abuse and renal-cell carcinoma. Bryden AA, Rothwell PJ, O’Reilly PH. Lancet. 1995 Nov 11;346(8985):1306-7
164. At what price, glory? Severe cholestasis and acute renal failure in an athlete abusing stanozolol. Yoshida EM, Karim MA, Shaikh JF, Soos JG, Erb SR. CMAJ. 1994 Sep 15;151(6):791-3
165. Severe cholestasis with kidney failure from anabolic steroids in a body builder. Habscheid W, Abele U, Dahm HH. Dtsch Med Wochenschr. 1999 Sep
166. The incidence of post-operative renal failure in obstructive jaundice. Dawson JL. Br J Surg 1965;52:663-665.
167. Acute renal failure complicating muscle crush injury. Abassi ZA, Hoffman A, Better OS. Semin Nephrol. 1998 Sep;18(5):558-65
168. Rhabdomyolysis in a bodybuilder using anabolic steroids. Hageloch W, Appell HJ, Weicker H. Sportverletz Sportschaden. 1988 Sep;2(3):122-5.
169. Atraumatic rhabdomyolysis in a 20-year-old bodybuilder. Morocco PA.J Emerg Nurs. 1991 Dec;17(6):370-2.
170. Continuous veno-venous hemofiltration for the immediate management of massive rhabdomyolysis after fulminant malignant hyperthermia in a bodybuilder. Schenk MR, Beck DH, Nolte M, Kox WJ. Anesthesiology. 2001 Jun;94(6):1139-41.
171. Rhabdomyolysis in a bodybuilder using steroids. Daniels JM, van Westerloo DJ, de Hon OM, Frissen PH. Ned Tijdschr Geneeskd. 2006 May 13;150(19):1077-80.
172. Hypertension and the kidney. Hohenstein K, Watschinger B. Wien Med Wochenschr. 2008;158(13-14):359-64.
173. Hepatic effects of 17 alpha-alkylated anaboli-androgenic steroids. HIV Hotline. 1998 Dec;8(5-6):2-5.
174. Methyltestosterone, related steroids, and liver function. A deLorimier et al. Arch Inter Med Vol. 116 Aug 1965 p 289-94
175. Jaundice associated with norbolethone (Nilevar) therapy. Shaw RK et al. Ann Intern Med 52:428-34 1960.
176. Androgenic/Anabolic steroid-induced toxic hepatitis. Stimac D, Miliç S, Dintinjana RD, Kovac D, Ristiç S. J Clin Gastroenterol. 2002 Oct;35(4):350-2.
177. Review of oxymetholone: a 17 alpha-alkylated anabolic-androgenic steroid. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd. Clin Ther. 2001 Jun;23(6):789-801; discussion 771
178. A pilot study of anabolic steroids in elderly patients with hip fractures. Sloan JP, Wing P, Dian L, Meneilly GS. J Am Geriatr Soc. 1992 Nov;40(11):1105-11.
179. Effects of long-term use of testosterone enanthate. II. Effects on lipids, high and low density lipoprotein cholesterol and liver function parameters. Tyagi A, Rajalakshmi M. et al. Int J Androl. 1999 Dec;22(6):347-55
180. Cellular distribution of androgen receptors in the liver. Hinchliffe SA, Woods S, Gray S, Burt AD. J Clin Pathol. 1996 May;49(5):418-20.
181. Liver toxicity of a new anabolic agent: methyltrienolone (17-alphamethyl-4,9,11-estratriene-17 beta-ol-3-one). Kruskemper, Noell. Steroids. 1966 Jul;8(1):13-24
182. T. Feyel-Cabanes, Compt. Rend. Soc. Biol. 157, 1428 (1963)
183. Anabolic-androgenic steroids and liver injury.M Sanchez-Osorio et al. Liver International ISSN 1478-3223 p. 278-82.
184. Androgenic/Anabolic steroid-induced toxic hepatitis. Stimac D et al. J Clin Gastroenterol. 2002 Oct;35(4):350-2.
185. Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Beuers U. Nat Clin Pract Gastroenterol Hepatol 2006; 3:318-28.
186. Peliosis hepatis in a young adult bodybuilder. Cabasso A. Med Sci Sports Exerc. 1994 Jan;26(1):2-4.
187. Bleeding esophageal varices associated with anabolic steroid use in an athlete. Winwood PJ et al. Post-Grad Med J 1990; 66:864-65.
188. Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone). Hernandez-Nieto L, Bruguera M, Bombi J, Camacho L, Rozman C. Cancer. 1977 Oct;40(4):1761-4
189. Hepatocellular carcinoma in the non-cirrhotic liver. Evert M, Dombrowski F. Pathologe. 2008 Feb;29(1):47-52
190. Intratesticular leiomyosarcoma in a young man after high dose doping with Oral-Turinabol: a case report. Cancer. Froehner M, Fischer R, Leike S, Hakenberg OW, Noack B, Wirth MP. 1999 Oct 15;86(8):1571-5.
191. Hepatocellular carcinoma associated with recreational anabolic steroid use. Gorayski P, Thompson CH, Subhash HS, Thomas AC. Br J Sports Med. 2008 Jan;42(1):74-5; discussion 75.
192. Bodybuilder death steroids warning. Express and Star 2008 09/04. Epub. www.expressandstar.com
193. Effect of testosterone and anabolic steroids on the size of sebaceous glands in power athletes. Kiraly CL et al. Am J Dermatopathol, 1987 Dec, 9:6,515-9.
194. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia, and hirsutism. Battmann T. et al. J Steroid Biochem Mol Biol. 1994 Jan;48(1):55-60.
195. Androgenetic alopecia and current methods of treatment. Bienová M, Kucerová R. et al. Acta Dermatovenerol Alp Panonica Adriat. 2005 Mar;14(1):5-8.
196. Molecular mechanisms of androgenetic alopecia. Trüeb RM. Exp Gerontol. 2002 Aug-Sep;37(8-9):981-90.
197. The inheritance of common baldness: two B or not two B? Kuster W, Happle R. J Am Acad Dermatol 1984; 11:921-26.
198. Polymorphism of the Androgen Receptor Gene is Associated with Male Pattern Baldness. Justine A Ellis, Margaret Stebbing and Stephen B Harrap. Journal of Investigative Dermatology (2001) 116,452-455.
199. EDA2R is associated with androgenetic alopecia. Prodi DA, Pirastu N, et al. J Invest Dermatol. 2008 Sep;128(9):2268-70. Epub 2008 Apr 3.
200. Current understanding of androgenetic alopecia. Part I: Etiopathogenesis. Hoffmann R, Happle R. European Journal of Dermatology. Volume 10, Number 4,319-27, June 2000
201. Estrogen and progesterone receptors in androgenic alopecia versus alopecia areata. Wallace ML, Smoller BR. Am J Dermatopathol. 1998 Apr;20(2):160-3
202. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Franke WW, Berendonk B. Clin Chem. 1997 Jul;43(7):1262-79.
203. Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency.Faustini-Fustini, M. et al. Mol Cell Endocrinol. 2001 Jun 10;178(1-2):215-20.
204. Effects of estrogen on growth plate senescence and epiphyseal function. M Weise, S De-Levi et al. Proc Natl Acad Sci June 5,2001 pp. 6871-6876.
205. The results of short-term (6 months) high-dose testosterone treatment on bone age and adult height in boys of excessively tall stature. Brämswig JH, von Lengerke HJ et al. Eur J Pediatr. 1988 Nov;148(2):104-6.
206. Oxandrolone in constitutional delay of growth: analysis of the growth patterns up to final stature. Bassi F, Neri AS, Gheri RG, Cheli D, Serio M.J Endocrinol Invest. 1993 Feb;16(2):133-7.
207. Pectoralis maior tendon rupture and anabolic steroids in anamnesis–a case review. März J, Novotn P. Rozhl Chir. 2008 Jul;87(7):380-3.
208. Successive ruptures of patellar and Achilles tendons. Anabolic steroids in competitive sports. Isenberg J, Prokop A, Skouras E. Unfallchirurg. 2008 Jan;111(1):46-9
209. Biomechanical responses of different rat tendons to nandrolone decanoate and load exercise. Marqueti RC, Prestes J, Wang CC, et al. Scand J Med Sci Sports. 2010 Jul 29.
210. The effect of local use of nandrolone decanoate on rotator cuff repair in rabbits. Papaspiliopoulos A, Papaparaskeva K, Papadopoulou E, et al. J Invest Surg. 2010 Aug;23(4):204-7.
211. Self-reported anabolic-androgenic steroids use and musculoskeletal injuries: findings from the center for the study of retired athletes health survey of retired NFL players. Horn S, Gregory P, Guskiewicz KM. Am J Phys Med Rehabil. 2009 Mar;38(3):192-200.
212. Salt, hypertension, and edema. Rössler R. Internist (Berl). 1976 Oct;17(10):489-93. Review.
213. Sex hormone effects on body fluid regulation. Stachenfeld NS. Exerc Sport Sci Rev. 2008 Jul;36(3):152-9.
214. Effect of ovarian steroids on vasopressin secretion. Forsling, M. L., P. Stromberg, and M. Akerlund. J. Endocrinol. 95: 147-151, 1982
215. Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. Nina S. Stachenfeld, Loretta Dipietro, Steven F. Palter, and Ethan R. Nadel Am J Physiol Regul Integr Comp Physiol 274:R187-R195, 1998.
216. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. Johannsson G, Gibney J, et al. J Clin Endocrinol Metab. 2005 Jul;90(7):3989-94. Epub 2005 Apr 12.
217. Casner, S. W., Early, R.G., and Carlson, B.R. Journal of Sports Med and Phys Fitness, 1971 11,98.
218. The effects of anabolic steroids on growth, body composition, and metabolism in boys with chronic renal failure on regular hemodialysis. Jones RW, El Bishti MM et al. J Pediatr. 1980 Oct;97(4):559-66.
219. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. Storer TW, Woodhouse LJ, J Clin Endocrinol Metab. 2005 Aug;90(8):4474-82. Epub 2005 May 24.
220. Bodybuilders’ Body Composition: Effect of Nandrolone Decanoate. VAN MARKEN LICHTENBELT, W. D., F. HARTGENS, N. B. J. VOLLAARD, S. EBBING, and H. KUIPERS. Med. Sci. Sports Exerc., Vol. 36, No.3, pp. 484-489, 2004.
221. Severe laryngitis following chronic anabolic steroid abuse. Ray S, Masood A, Pickles J, Moumoulidis I. J Laryngol Otol.2008 Mar;122(3):230 2. Epub 2007 May 14
222. Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage Heather L LaMarca1 and Jeffrey M Rosen. Breast Cancer Res. 2007;9(4): 304.
223. Androgens and mammary growth and neoplasia. Dimitrakakis Zhou J, Bondy CA. Fertil Steril. 2002 Apr;77 Suppl 4:26-33.
224. Surgical treatment of gynecomastia in the body builder. Aiache AF Plast Reconstr Surg. 1989 Jan;83(1):61-6.
225. Roles of estrogen and progesterone in normal mammary gland development insights from progesterone receptor null mutant mice and in situ localization of receptor. Shyamala G. Trends Endocrinol Metab 1997 Jan-Feb;8(1):34-9.
226. A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents. Baker J. J Voice 1999 Dec;13(4):496-507.
227. Fundamental voice frequence during normal and abnormal growth, and after androgen treatment. Vuorenkoski V, Lenko HL, Tjernlund P, Vuorenkoski L, Perheentupa J. Arch Dis Child. 1978 Mar;53(3):201-9.
228. Fluoxymesterone therapy in anemia of patients on maintenance hemodialysis: comparison between patients with kidneys and anephric patients. Acchiardo SR, Black WD.J Dial. 1977;1(4):357-66.
229. Testosterone therapy in women: its role in the management of hypoactive sexual desire disorder. Abdallah RT, Simon JA. Int J Impot Res. 2007 Sep-Oct;19(5):458-63. Epub 2007 Jun 21.
230. Virilization caused by methandrostenolone-containing cream in 2 prepubertai girls. Sorgo W, Zachmann M. Hely Paediatr Acta. 1982 Sep;37(4):401-6.
231. Change in speaking fundamental frequency in hormone-treated patients with Turner’s syndrome–a longitudinal study of four cases. Andersson-Wallgren G, Albertsson-Wikland K. Acta Paediatr. 1994 Apr;83(4):452-5.
232. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Decadurabolin). The effects of medication for one year. Gerritsma EJ, Brocaar MP, Hakkesteegt MM, Birkenhäger JC. Clin Otolaryngol Allied Sci. 1994 Feb;19(1):79-84.
233. Idiopathic isolated clitoromegaly: A report of two cases. Eray Copcu1, Alper Aktas et al. Reproductive Health 2004, 1:4.
234. Two Cases of Clitoromegaly. Clitoral Reduction Preserving Sensation of Clitoris. NODA KOJIRO (Chiba-ken Kodomo Byoin), UDAGAWA AKIKAZU (Chiba-ken Kodomo Byoin) et al. Journal of Japan Society of Aesthetic Plastic Surgery VOL.22;NO.3;PAGE.90-95(2000).
235. Evaluation and Treatment of Women with Hirsutism. MELISSA H. HUNTER, M.D., and PETER J.CAREK, M.D. Am Fam Physician 2003;67:2565- 72.
236. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. M Slagter, L Gooren et al. J Histochem Cytochem.54(8): 905-910, 2006.
237. Behavioural effects of androgen in men and women. Christiansen K. J Endocrinol. 2001 Jul;170(1):39-48.
238. Exogenous testosterone enhances responsiveness to social threat in the neural circuitry of social aggression in humans. Hermans , Ramsey NF, van Honk J. Biol Psychiatry. 2008 Feb 1;63(3):263-70. Epub 2007 Aug 28.
239. Underground Steroid Handbook II. Daniel Duchaine. 1989. HLR technical book, Venice, CA
240. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ.J Clin Endocrinol Metab. 1994 Aug;79(2):561-7.
241 The effects of exogenous testosterone on sexuality and mood of normal men. Anderson RA, Bancroft J, Wu FC. J Clin Endocrinol Metab. 1992
242. Psychological and serum homovanillic acid changes in men administered androgenic steroids. Hannan CJ Jr, Friedl KE, Zold A, Kettler TM, Plymate SR. Psychoneuroendocrinology. 1991;16(4):335-43.
243. Psychosexual effects of three doses of testosterone cycling in normal men. Yates WR et al. Biol Psychiatry. 1999;45:254-60.
244. Effects of supraphysiological doses of testosterone on mood and aggression in normal men. H Pope, E Kouri et al. Arch Gen Psychiatry. 2000;57:133-140.
245. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. T Pagonis et al. Eur Psych 21 (2006) 551-62.
246. Violence toward women and illicit androgenic-anabolic steroid use. Choi PY, Pope HG Jr. Ann Clin Psychiatry. 1994 Mar;6(1):21-5.
247. Criminality among individuals testing positive for the presence of anabolic androgenic steroids. Klötz F, Garle M, Granath F, Thiblin I. Arch Gen Psychiatry. 2006 Nov;63(11):1274-9.
248. Homicide and near-homicide by anabolic steroid users. Pope HG Jr, Katz DL. J Clin Psychiatry. 1990 Jan;51(1):28-31.
249. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. K Bower, G Eliopulos et al. Am J Psychiatry 1990; 147:510-12.
250. Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Pope HG Jr, Gruber AJ, Choi P, Olivardia R, Phillips KA.Psychosomatics. 1997 Nov-Dec;38(6):548-57.
251. “Chocolate addiction”: a preliminary study of its description and its relationship to problem eating. Hetherington MM, MacDiarmid JI. Appetite. 1993 Dec;21(3):233-46.
252. Reinforcing aspects of androgens. Wood RI. Physiol Behav.2004 Nov 15;83(2):279-89.
253. Expression of testosterone conditioned place preference is blocked by peripheral or intra-accumbens injection of alpha-flupenthixol. Packard MG, Schroeder JP, Alexander GM. Horm Behav. 1998 Aug;34(1):39-47.
254. Role of dopamine receptor subtypes in the acquisition of a testosterone conditioned place preference in rats. Schroeder JP, Packard MG. Neurosci Lett. 2000 Mar 17;282(1-2):17-20.
255. Increased dopamine transporter density in the male rat brain following chronic nandrolone decanoate administration. Kindlundh AM, Rahman S, Lindblom J, Nyberg F. Neurosci Lett. 2004 Feb 12;356(2):131-4.
256. Abuse liability of testosterone. Fingerhood MI, Sullivan JT et al. J Psychopharmacol 1997; 11(1):59-63.
257. Anabolic steroid withdrawal depression: a case report. Allnutt S, Chaimowitz G. Can J Psychiatry. 1994 Jun;39(5):317-8.
258. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. Malone DA Jr, Dimeff RJ. J Clin Psychiatry. 1992 Apr;53(4):130-2.
259. New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence? Dudley M, Hadzi-Pavlovic D, Andrews D, Perich T. Aust NZJ Psychiatry. 2008 Jun;42(6):456-66. 260. Anabolic androgenic steroids and suicide. Thiblin I, Runeson B, Rajs J.Ann Clin Psychiatry. 1999 Dec;11(4):223-31.
261. Testosterone deficiency and mood in aging men: pathogenic and therapeutic interactions. Seidman SN. World J Biol Psychiatry. 2003 Jan;4(1):14-20.
262. Treatment strategies of withdrawal from long-term use of anabolicandrogenic steroids. MedraÊ M, Tworowska U. Pol Merkur Lekarski. 2001 Dec;11(66):535-8. Review
263. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Am J Sports Med. 1992 NovDec;20(6):717-24.
264. Insomnia: pathophysiology and implications for treatment. Roth T, Roehrs T, Pies R. Sleep Med Rev. 2007 Feb;11(1):71-9. Epub 2006 Dec 18.
265. When does estrogen replacement therapy improve sleep quality? Polo-Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. Am J Obstet Gynecol. 1998 May;178(5):1002-9.
266. Adverse effects of anabolic androgenic steroids on the cardiovascular, metabolic and reproductive systems of anabolic substance abusers. Tuomo Karila. Publications of the National Public Health Institute ISBN 951-740-388-2
267. Reversible hypogonadism and azoospermia as a result of anabolicandrogenic steroid use in a bodybuilder with personality disorder. A case report. Boyadjiev NP, Georgieva KN, Massaldjieva RI, Gueorguiev Sl. J Sports Med Phys Fitness. 2000 Sep;40(3):271-4.
268. Conservative management of azoospermia following steroid abuse. M.R. Gazvani et al. Human Reprod 12(8) (1997) pp. 1706-08.
269. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet, 1990 20;336(8721):955-9.
270. Effects of chronic testosterone administraton in normal men: saferty and efficacy of high dose testosterone and parallel dosedependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. Matsumoto AM. J Clin Endocrinol Metab 1990; 70:282-87.
271. Restorative increases in serum testosterone levels are significantly correlate to improvements in sexual functioning. A Seftel, R Mack et al.J Androl 25(6) 2004 pp. 963-72.
272. Sexual functioning of male anabolic steroid abusers. Moss HB, Panzak GL, Tarter RE. Arch Sex Behav. 1993 Feb;22(1):1-12.
273. Low sex hormone-binding globulin and testosterone levels in association with erectile dysfunction among human immunodeficiency virus-infected men receiving testosterone and oxandrolone. Wasserman P, Segal-Maurer S, Rubin D. J Sex Med. 2008 Jan;5(1):241-7. Epub 2007 Oct 24.
274. Of mice and men: the many guises of estrogens. Simpson ER, Jones ME. Ernst Schering Found Symp Proc. 2006;(1):45-67.
275. Testosterone-induced priapism in Klinefelter syndrome. Ichioka K, Utsunomiya N, Kohei N, Ueda N, Inoue K, Terai A. Urology. 2006 Mar;67(3):622.e17-8. Epub 2006 Feb 28.
276. Severe priapism as a complication of testosterone substitution therapy. Zelissen PM, Stricker BH. Am J Med. 1988 Aug;85(2):273-4
277. Testosterone induced priapism in two adolescents with sickle cell disease. Slayton W, Kedar A, Schatz D. J Pediatr Endocrinol Metab. 1995 Jul-Sep;8(3):199-203.
278. Benign hypertrophy and carcinoma of the prostate. Moore RA. Surgery 1944;16:152-67.
279. Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer. Morgentaler A. J Sex Med. 2008 Aug;5(8):1834-40.
280. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Int J Impot Res. 2008 Jul 17. [Epub ahead of print]
281. Long-term psychiatric and medical consequences of anabolicandrogenic steroid abuse: A looming public health concern? Kanayama G, Hudson JI, Pope HG Jr. Drug Alcohol Depend. 2008 Nov 1;98(1-2):1-12. Epub 2008 Jul 2.
282. The many faces of testosterone. Bain J. Clin Interv Aging. 2007;2(4):567-76.
283. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Guay AT, Perez JB, Fitaihi WA, Vereb M. Endocr Pract. 2000 Mar-Apr;6(2):132-8.
284. Adenocarcinoma of prostate in 40 year old body-builder. Roberts TJ, Essenhigh DM. Lancet 1986;2:742.
285. Testosterone therapy for men at risk for or with history of prostate cancer. Morgentaler A. Curr Treat Options Oncol. 2006 Sep;7(5):363-9.
286. Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Barqawi A, Crawford ED. Int J Impot Res. 2006 JulAug;18(4):323-8. Epub 2005 Nov 10.
287. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. Sasagawa I, Nakada T, Kazama T, Satomi S, Terada T, Katayama T. Int Urol Nephrol. 1990;22(3):279-84.
288. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Minnemann T, Schubert M, Hübler D, GouniBerthold I, Freude S, Schumann C, Oettel M, Ernst M, Mellinger U, Sommer F, Krone W, Jockenhövel F. Aging Male. 2007 Sep;10(3):155-8.
289. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadis. A Randomized Controlled Trial Leonard S. Marks, MD; Norman A. Mazer, MD, et al. JAMA. 2006;296:2351-2361.
290. Prognostic value of serum markers for prostate cancer. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P. Scand J Urol Nephrol Suppl. 2005 May;(216):64-81.
291. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Br J Urol. 1993 Apr;71(4):445-50.
292. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. Kaplan SA, Roehrborn CG, McConnell JD et al. J Urol. 2008 Sep;180(3):1030-2; discussion 1032-3. Epub 2008 Jul 17.
293. Winning is the Only Thing. Randy Roberts, James S. Olson.JHU Press, 1991. ISBN 0801842409
294. Androgen or Estrogen Effects on Human Prostate. B.Jin, L Turner et al. J Clin Endocrinol Metab. 1996;81(12):4290-95.
295. Fingerprinting the diseased prostate: associations between BPH and prostate cancer. Shah US, Getzenberg RH. J Cell Biochem. 2004 Jan 1;91(1):161-9.
296. Estrogen-regulated development and differentiation of the prostate. McPherson SJ, Ellem SJ, Risbridger GP. Differentiation. 2008 Jul;76(6):660-70. Epub 2008 Jun 28.
297. Estrogen action on the prostate gland: a critical mix of endocrine. and paracrine signaling. G Risbridger, S Ellem et al. J Mol Endocrino
298. Effects of androgen therapy on prostatic markers in hemodialyzed patients. Teruel JL, Aguilera A, Avila C, Ortuño J. Scand J Urol Nephrol 1996 Apr;30(2):129-31.
299. The role of aromatization in testosterone supplementation. Effects on cognition in older men. M.M. Cherrier, A.M. Matsumoto et al Neurology 2005;64:290-96.
300. Use of anabolic steroids and associated health risks among gay men attending London gyms. Bolding G, Sherr L, Elford J. Addiction. 2002 Feb;97(2):195-203.
301. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Korkia P, Stimson GV. Int J Sports Med. 1997 Oct;18(7):557-62.
302. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. C Meriggola et al. J Clin Endocrinol Metab 81(8) 3018-23, 1996.
303. HPGA normalization protocol after androgen treatment. N Vergel, AL Hodge, MC Scally. Program for Wellness Restoration.
304. An update to the Crisler HCG Protocol. John Crisler, DO. 2004.
305. Testicular responsiveness following chronic administration of hCG (1500 IU every six days) in untreated hypogonadotropic hypogonadism. Balducci R, Toscano V, Casilli D, Maroder M, Sciarra F, Boscherini B. Horm Metab Res. 1987 May;19(5):216-21.
306. Estrogen suppression in males: metabolic effects. Mauras N, O’Brien KO, Klein KO, Hayes V. J Clin Endocrinol Metab. 2000 Jul;85(7):2370-7.
307. Progesterone and testosterone in combination act in the hypothalamus of castrated rams to regulate the secretion of LH. Turner Al, Tilbrook AJ, Clarke IJ, Scott CJ.J Endocrinol. 2001 May;169(2):291-8.
308. Football; Alzado Tumor is Rare and Deadly. Elisabeth Rosenthal. NY Times. July 4, 1991.
309. Primary central nervous system lymphoma. O’Neill BP, Illig JJ. Mayo Clin Proc. 1989 Aug;64(8):1005-20.
310. Sports People: Football; Alzado Talks. NY Times. Associated Press Report. June 28,1991.
311. Alzado believed drug killed him – Ex-Raider star dead from brain cancer. Associated Press. May 15, 1992.
312. 54-year-old man with breast cancer after prolonged testosterone therapy. Sorscher S, Krause W. Clin Adv Hematol Oncol. 2005 Jun;3(6):475; discussion 476.
313. Androgen therapy. Longson D. Practitioner. 1972 Mar;208(245):33848.
314. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Mårin P, Krotkiewski M, Björntorp P. Eur J Med. 1992 Oct;1(6):329-36.
315. Effects of androgen therapy on adipose tissue and metabolism in older men. Schroeder ET, Zheng L, Ong MD, Martinez C, Flores C, Stewart Y, Azen C, Sattler FR. J Clin Endocrinol Metab. 2004 Oct;89(10):4863-72.
316. Insulin sensitivity, insulin secretion, and abdominal fat: the insulin resistance atherosclerosis study (IRAS) family study. Wagenknecht LLI Langerfeld CD et al. Diabetes 52:2490-2494.
317. Recent developments in the toxicology of anabolic steroid Graham S, Kennedy M. Drug Saf. 1990 Nov-Dec;5(6):458-76.
318. Insulin resistance and diminished glucose tolerance in powerlit ingesting anabolic steroids. Cohen JC, Hickman R. J Clin Endoc Metab. 1987 May;64(5):960-3.
319. Insulin action and dynamics modelled in patients taking the anabolic steroid methandienone (Dianabol). Godsland IF, Shennan NM, Wynn V. Clin Sci (Lond). 1986 Dec;71(6):665-73
320. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh AB, Hsia S. et al. J Clin Endocrinol Metab. 2002 Jan;87(1):136-43.
321. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. Hobbs CJ, Jones RE, Plymate SR. et al. J Clin Endocrinol Metab. 1996 Apr;81(4):1582-5.
322. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Korkia P, Stimson GV. Int J Sports Med. 1997 Oct;18(7):557-62.
323. Cardiovascular complications of respiratory diseases. Chowdhuri S, Crook ED, Taylor HA Jr, Badr MS. Am J Med Sci. 2007 Nov;334(5):361-80.
324. Obesity and hormonal factors in sleep and sleep apnea. Wittels EH. Med Clin North Am. 1985 Nov;69(6):1265-80.
325. Metabolic aspects of sleep apnea. Grunstein RR. Sleep. 1996 Dec;19(10 Suppl):S218-20.
326. Testosterone replacement therapy for older men. Borst SE, Mulligan T. Clin Interv Aging. 2007;2(4):561-6.
327. The Short-Term Effects of High-Dose Testosterone on Sleep, Breathing, and Function in Older Men Peter Y. Liu, Brendon Yee et al. The Journal of Clinical Endocrinology & Metabolism Vol. 88, No.8 3605-3613
328. Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration. Johnson MW, Anch AM, Remmers JE. Am Rev Respir Dis. 1984 Jun;129(6):1023-5.
329. Testosterone dose-response relationships in healthy young men. Shalender A, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: e1172-81 2001
330. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM.Am J Physiol Endocrinol Metab. 283(6) Dec (2002):E1214-22. Epub 2002 Aug 27.
331. Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. Schroeder et al. Am J Physiol Endocrinol Metab 284: E120-28
332. Behind the Scenes: Hypertrophy. Gene. Mind and Muscle Magazine 5/2005
333. Regulation of skeletal muscle fiber size, shape and function. J Biomech. 24(suppl1):123-33 (1991)
334. Initial events in exercise-induced muscular injury. Med Sci Sports Exerc 22(4):429-35 (1990)
335. Myostatin negatively regulates satellite cell activation and selfrenewal. J Cell Biol. 162:1135-47 (2003)
336. Signaling satellite-cell activation in skeletal muscle: markers, models, stretch, and potential alternative pathways. A Wozniak, J Kong et al. Muscle Nerve 31:283-300 (2005)
337. Effects of physical exercise on phospholipid fatty acid composition in skeletal muscle. Agneta Andersson et al. Am J Physiol. 274 (Endocrinol. Metab. 37): E432-8 (1998)
338. Effects of Exercise on parameters of blood coagulation, platelet function and the prostaglandin system. H Sinzinger, 1 Virgolini. Sports Medicine 6:238-45 (1988)
339. Mechanical stretch induces activation of skeletal muscle satellite cells in vitro. Tatsumi R, Sheehan SM et al. Exp Cell Res 267(1) 107-14 (2001) 340. Release of hepatocyte growth factor from mechanically stretched skeletal muscle satellite cells and role of pH and Nitric Oxide. Ryuichi Tatsumi et al. Mol Biol of the Cell 13 p 2909-18 (2002)
341. Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J Clin Inv 98:2604-11
342. The role of prostaglandins in bone formation. Harada SI, Balena R et al. Connect Tissue Res. 1995;31(4)279-82
343. Prostaglandin F2a stimulates proliferation of clonal osteoblastic MC3T3-E1 cells by up-regulation of Insulin-like Growth Factor 1 receptors. Yoshiyuky Hakeda et al. J Biol Chem 266(31): 21044-50 (1991)
344. Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal bone. McCarthy TL, Centrella Met al. Endocrinology 128(6):2895-900 (1991)
345. Sequence of IGF-I, IGF-II, and HGF expression in regenerating skeletal muscle. Hayashi S et al. Histochem Cell Biol. 122(5):427-34 (2004)
346. Expression of insulin like growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. G Mckoy, W Ashley et al. J Physiol 516(2) 583-92 (1999)
347. Expression of fibrolast growth factor family during postnatal skeletal muscle hypertrophy. P Mitchell, T Steenstrup, K Hannon.J Applied Physiol 86:313-19 (1999)
348. Fibroblast growth factor is stored in fiber extracellular matrix and plays a role in regulating muscle hypertrophy. Medicine and Science in Sports and Exercise 21(5) S173-80 (1989)
349. The insulin-like effect of muscle contraction. Ivy JL. Exerc Sport Sci Rev. 1987;15:29-51.
350. The role of prostaglandins as modulators of insulin-stimulated glucose metabolism in skeletal muscle. Leighton B et al. Horm Metab Res Suppl. 22:89-95 (1990)
351. Differential effects of prostaglandins derived from n-6 and n-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Dilprit Bagga et al.PNAS 100(4) 1751-56 (2003)
352. The role of arachidonic acid metabolism in the activities of Interleukin 1 and 2.W Farrar, J Humes. J of Immunol 135(2) 1153-9 (1985)
353. Regulation of protein synthesis associated with skeletal muscle hypertrophy by insulin-, amino acid and exercise-induced signaling. D Bolster, L Jefferson, S Kimball. Proc of the Nutrition Society 63: 351-56 (2004).